The estimated Net Worth of Eugene Myron Holuka is at least $1.28 Thousand dollars as of 13 March 2024. Eugene Holuka owns over 2,415 units of Citius Pharmaceuticals Inc stock worth over $1,280 and over the last 8 years he sold CTXR stock worth over $0. In addition, he makes $0 as Independent Director at Citius Pharmaceuticals Inc.
Eugene has made over 1 trades of the Citius Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 2,415 units of CTXR stock worth $48 on 13 March 2024.
The largest trade he's ever made was exercising 2,415 units of Citius Pharmaceuticals Inc stock on 13 March 2024 worth over $48. On average, Eugene trades about 201 units every 0 days since 2016. As of 13 March 2024 he still owns at least 2,415 units of Citius Pharmaceuticals Inc stock.
You can see the complete history of Eugene Holuka stock trades at the bottom of the page.
Dr. Eugene Holuka serves as Independent Director of the Company. Dr. Holuka has served as a director of the Company since June 2016. Dr. Holuka is an internist and has practiced in critical care medicine for almost thirty years. He is presently an attending physician at the Staten Island University Hospital where he has practiced since 1991. Dr. Holuka has also served as an Adjunct Clinical Assistant Professor at the Touro College of Osteopathic Medicine since 2011. Prior to the acquisition of LMB by the Company in March 2016, he was a member of the LMB Scientific Advisory Board from April 2014 until the present day. Dr. Holuka received the Ellis Island Medal of Honor in 2000 and has served on the NECO Committee Board since 2005. He was an Executive Committee Member on the Forum’s Children Foundation from 2000 until 2008.
Eugene Holuka is 60, he's been the Independent Director of Citius Pharmaceuticals Inc since 2016. There are 11 older and 2 younger executives at Citius Pharmaceuticals Inc. The oldest executive at Citius Pharmaceuticals Inc is Suren Dutia, 77, who is the Independent Director.
Eugene's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016.
Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over $0 worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth $15,819,221 . The most active insiders traders include Leonard L Mazur, Myron Z Holubiak, and Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of $523,934. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth $48.
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include: